Author

C. Solis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Evolutionary Biology· 1 Pathology· 1 Scientific Communication & Education· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Assay:clinical cohort / trial· 1 Research Focus:database / resource· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

W. Dong· 2 shared A. Braxton· 1 shared A. Jedlicka· 1 shared A. Johanson· 1 shared A. Novikova· 1 shared A. Pekosz· 1 shared A. Tebeje· 1 shared C. Brayton· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

W. Dong

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy

V. Rawat, P. DeLear, P. Prashanth, M. E. Ozgurses, A. Tebeje, P. A. Burns, K. O. Conger, C. Solis, Y. Hasnain, A. Novikova, J. E. Endress, P. Gonzalez-Sanchez, W. Dong, G. Stephanopoulos, G. M. DeNicola, , J. L. Coloff

The paper screens drugs in human physiologic medium and identifies uric acid as an inhibitor of rigosertib's efficacy.

bioRxiv · Jul 26, 2023Cancer Biology

Analysis of NIH K99/R00 Awards and the Career Progression of Awardees

N. C. Woitowich, S. R. Hengel, C. Solis, T. P. Vilgalys, J. Babdor, D. J. Tyrrell

This paper analyzes NIH K99/R00 awards and their impact on career progression, finding disparities in award receipt and success based on gender, institution, and race.

bioRxiv · Jan 26, 2023Scientific Communication & Education

Progression and Resolution of SARS-1 CoV-2 Infection in Golden Syrian Hamsters

K. Mulka, S. Beck, C. Solis, A. Johanson, S. Queen, M. McCarron, M. Richardson, R. Zhou, P. Marinho, A. Jedlicka, S. Guerrero-Martin, E. Shirk, A. Braxton, J. Brockhurst, P. Creisher, , J. Mankowski

This study tracks SARS-CoV-2 infection progression in golden Syrian hamsters, showing weight loss, lung damage, and resolution over time.

bioRxiv · Jun 25, 2021Pathology

Assessing in vivo mutation frequencies and creating a high-resolution genome-wide map of fitness costs of Hepatitis C virus

K. H. Tisthammer, C. Solis, F. Oracles, M. Nzerem, R. Winstead, W. Dong, J. B. Joy, P. S. Pennings

This study estimates in vivo fitness costs of HCV mutations using frequency-based analysis across 195 patients, revealing mutation type and genomic location effects on fitness costs.

bioRxiv · Oct 1, 2020Evolutionary Biology